09.01.2013 - Swiss Debiopharm Group (Lausanne) has licenced Chugai’s preclinical anti-cancer agent FF284.
The Tokyo-based Roche affiliate announced the deal on 8 January 2013, three weeks after the companies signed an agreement giving Debiopharm global rights to develop and commercialise the preclinical compound FF284 (now Debiopharm 1347). Chugai remain the rights to the Japanese market.
Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialise a companion diagnostic for FF284 (Debio 1347). According to the terms of the agreement, Debiopharm and the Roche daughter will conduct a Phase I dose escalation study. In return for the license, Chugai will receive an undisclosed upfront fee, milestone and royalty payments from Debiopharm.
Debio 1347 is an orally available small molecule targeting an undisclosed signalling pathway affecting solid tumour development
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.